GSK (NYSE:GSK) Stock Rating Lowered by Jefferies Financial Group

GSK (NYSE:GSK) was downgraded by research analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a report released on Tuesday, MarketBeat reports. They presently have a $39.50 price objective on the pharmaceutical company’s stock, down from their prior price objective of $53.00. Jefferies Financial Group’s target price points to a potential upside of 12.50% from the company’s current price.

A number of other research analysts have also recently commented on GSK. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Argus raised GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Barclays upgraded GSK to a “hold” rating in a research note on Tuesday, August 27th. Six analysts have rated the stock with a hold rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Trading Down 1.2 %

Shares of GSK stock opened at $35.11 on Tuesday. The firm has a fifty day moving average of $39.65 and a 200-day moving average of $40.84. The stock has a market cap of $72.77 billion, a price-to-earnings ratio of 22.80, a P/E/G ratio of 1.36 and a beta of 0.66. GSK has a 52-week low of $34.29 and a 52-week high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

Insider Activity at GSK

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of the firm’s stock in a transaction on Friday, September 27th. The shares were purchased at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the acquisition, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 10.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On GSK

Several hedge funds and other institutional investors have recently made changes to their positions in the company. 1832 Asset Management L.P. increased its position in GSK by 9.1% in the first quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock worth $132,000 after purchasing an additional 257 shares during the period. Boltwood Capital Management boosted its stake in shares of GSK by 2.5% in the 2nd quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock valued at $429,000 after purchasing an additional 270 shares during the last quarter. First Affirmative Financial Network grew its position in shares of GSK by 4.7% during the 2nd quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock worth $245,000 after buying an additional 283 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of GSK by 9.4% during the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock worth $137,000 after buying an additional 303 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. boosted its stake in GSK by 2.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock valued at $682,000 after acquiring an additional 323 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.